A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody
Status:
Not yet recruiting
Trial end date:
2026-12-31
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2 study of HST-1011, a CBL-B inhibitor, being developed for the treatment
of patients with advanced solid tumors, who relapsed while on or are refractory to approved
anti-PD(L)1 therapies or other standard of care.